Soluble interleukin‐2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer

Background. Previous studies have established that soluble interleukin‐2 receptor alpha (sIL‐2Rα) levels are elevated in ascites and sera from individuals with advanced ovarian cancer (International Federation of Gynecology and Obstetrics [FIGO] Stage III/IV). This study was undertaken to evaluate sIL‐2Rα levels in individuals with benign ovarian neoplasms and early stage ovarian cancer (FIGO Stage I/II). Comparison with CA 125 levels was performed to assess screening potential.

[1]  R. Kryscio,et al.  The efficacy of a sonographic morphology index in identifying ovarian cancer: a multi-institutional investigation. , 1994, Gynecologic oncology.

[2]  G. Mills,et al.  Levels of soluble interleukin-2 receptor-alpha are elevated in serum and ascitic fluid from epithelial ovarian cancer patients. , 1994, American journal of obstetrics and gynecology.

[3]  R. Bast,et al.  Elevation of multiple serum markers in patients with stage I ovarian cancer. , 1993, Journal of the National Cancer Institute.

[4]  G. Mills.  Introduction: Transmembrane signaling through hematopoietin receptors: interleukin-2 and erythropoietin , 1993 .

[5]  G. Mills,et al.  Transmembrane signaling by the interleukin-2 receptor: progress and conundrums. , 1993, Seminars in immunology.

[6]  J. Kennedy,et al.  Interleukin-2 receptor and ovarian cancer. , 1993, British Journal of Cancer.

[7]  S. Nicosia,et al.  High serum and ascitic soluble interleukin-2 receptor alpha levels in advanced epithelial ovarian cancer. , 1993, Blood.

[8]  Max H. Myers,et al.  Manual for Staging of Cancer , 1992 .

[9]  A. Sarandakou,et al.  Soluble interleukin‐2 receptors and other markers in primary lung cancer , 1991, Cancer.

[10]  L A Rubin,et al.  The soluble interleukin-2 receptor: biology, function, and clinical application. , 1990, Annals of internal medicine.

[11]  G. Eklund,et al.  Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. , 1990, Gynecologic oncology.

[12]  S. Barni,et al.  The biological significance of soluble interleukin-2 receptors in solid tumors. , 1990, European journal of cancer.

[13]  G. Mills,et al.  Increase of serum interleukin 2 receptor level in thermally injured patients. , 1989, Clinical immunology and immunopathology.

[14]  S. Barni,et al.  Increased Level of Soluble Interleukin-2 Receptor in Advanced Solid Tumors: A Preliminary Study , 1988, Tumori.

[15]  D. Nelson,et al.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. , 1985, Journal of immunology.

[16]  R. Scully,et al.  Medical progress: common epithelial cancer of the ovary (second of two parts) , 1985 .

[17]  R. Scully,et al.  Common epithelial cancer of the ovary (2). , 1985, The New England journal of medicine.

[18]  R. Scully,et al.  Common epithelial cancer of the ovary: second of two parts , 1985 .

[19]  R. Bast,et al.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.